Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up point in time (one day) blood collection at enrollment
Awards & highlights
Summary
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
Eligible Conditions
- Lung Cancer
- Colorectal Cancer
- Kidney Cancer
- Prostate Cancer
- Ovarian Cancer
- Bladder Cancer
- Uterine Cancer
- Pancreatic Cancer
- Liver Cancer
- Stomach Cancer
- Esophageal Cancer
- Breast Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ point in time (one day) blood collection at enrollment
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~point in time (one day) blood collection at enrollment
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Biomarker Evaluation
Trial Design
12Treatment groups
Experimental Treatment
Group I: UterineExperimental Treatment1 Intervention
Subjects with clinically confirmed uterine cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group II: StomachExperimental Treatment1 Intervention
Subjects with clinically confirmed stomach cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group III: ProstateExperimental Treatment1 Intervention
Subjects with clinically confirmed prostate cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group IV: PancreaticExperimental Treatment1 Intervention
Subjects with clinically confirmed or suspicion of pancreatic cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group V: OvarianExperimental Treatment1 Intervention
Subjects with clinically confirmed or suspicion of ovarian cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group VI: LungExperimental Treatment1 Intervention
Subjects with clinically confirmed lung cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group VII: LiverExperimental Treatment1 Intervention
Subjects with clinically confirmed liver cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group VIII: Kidney & Renal PelvisExperimental Treatment1 Intervention
Subjects with clinically confirmed or suspicion of kidney or renal pelvis cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group IX: EsophagealExperimental Treatment1 Intervention
Subjects with clinically confirmed esophageal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group X: ColorectalExperimental Treatment1 Intervention
Subjects with clinically confirmed colorectal cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group XI: BreastExperimental Treatment1 Intervention
Subjects with clinically confirmed breast cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Group XII: BladderExperimental Treatment1 Intervention
Subjects with clinically confirmed or suspicion of bladder cancer and who are treatment naive will provide a blood sample at time of enrollment. No additional blood draws will occur.
Find a Location
Who is running the clinical trial?
Exact Sciences CorporationLead Sponsor
33 Previous Clinical Trials
254,407 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger